Skip to main content
Main navigation
Home
SERVICES
About Us
PUBLICATIONS
PERSPECTIVES
RESOURCES
RESOURCES
Search
Publications
All
Antibodies
Gene Therapy
Vaccines
Brainstorms
A role for CD4+ NK1.1+ T lymphocytes as major histocompatibility complex class II independent helper cells in the generation of CD8+ effector function against intracellular infection.
[ Milestones ]
/
Advances in vaccine delivery: transcutaneous immunisation
[ Milestones ]
/
Analysis of granuloma formation in double cytokine-deficient mice reveals a central role for IL-10 in polarizing both T helper cell 1- and T helper cell 2-type cytokine responses in vivo.
[ Milestones ]
/
Critical roles for the Bcl-3 oncoprotein in T cell-mediated immunity, splenic microarchitecture, and germinal center reactions.
[ Milestones ]
/
Cytokines as determinants of disease and disease interactions.
[ Milestones ]
/
Decreased resistance of TNF receptor p55- and p75-deficient mice to chronic toxoplasmosis despite normal activation of inducible nitric oxide synthase in vivo.
[ Milestones ]
/
Designing Labs for Lean Operation
[ Milestones ]
/
Dry Formulation for Transcutaneous Immunization.
[ Milestones ]
/
Failure of P strain mice to respond to vaccination against schistosomiasis correlates with impaired production of IL-12 and up-regulation of Th2 cytokines that inhibit macrophage activation.
[ Milestones ]
/
Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis
[ Milestones ]
/
GLP Requirements and Current Practices
[ Milestones ]
/
IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis.
[ Milestones ]
/
Immune responses in mice deficient in Ly-GDI, a lymphoid-specific regulator of Rho GTPases.
[ Milestones ]
/
Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms
[ Milestones ]
/
In the absence of endogenous IFN-gamma, mice develop unimpaired IL-12 responses to Toxoplasma gondii while failing to control acute infection.
[ Milestones ]
/
In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha.
[ Milestones ]
/
In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleukin 12 by dendritic cells and their redistribution to T cell areas.
[ Milestones ]
/
Incorporating Lean Principles into Pharmaceutical QC Laboratory Design: building design influencing laboratory behaviours and effectiveness
[ Milestones ]
/
Inducible nitric oxide is essential for host control of persistent but not acute infection with the intracellular pathogen Toxoplasma gondii.
[ Milestones ]
/
Infection of mice lacking the common cytokine receptor gamma-chain (gamma(c)) reveals an unexpected role for CD4+ T lymphocytes in early IFN-gamma-dependent resistance to Toxoplasma gondii.
[ Milestones ]
/
Interaction between the innate and the acquired immune system following infection of different mouse strains with Leishmania major
[ Milestones ]
/
Interferon consensus sequence binding protein-deficient mice display impaired resistance to intracellular infection due to a primary defect in interleukin 12 p40 induction.
[ Milestones ]
/
Leishmania major-infected C3H mice treated with anti-IL-12 mAb develop but do not maintain a Th2 response
[ Milestones ]
/
Mechanisms of innate resistance to Toxoplasma gondii infection
[ Milestones ]
/
Mice deficient in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture.
[ Milestones ]
/
Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice.
[ Milestones ]
/
Partially protective vaccination permits the development of latency in a normally virulent strain of Toxoplasma gondii.
[ Milestones ]
/
Perforin-mediated cytolysis plays a limited role in host resistance to Toxoplasma gondii
[ Milestones ]
/
Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe
[ Milestones ]
/
Pre-Approval Access: Can Compassion, Business, and Medicine Coexist?
[ Milestones ]
/
Principles of transcutaneous immunization using cholera toxin as an adjuvant
[ Milestones ]
/
Regulations and Science: Common Sense Approaches to Accelerating Patient Access to Novel Gene and Cell Therapies
[ Milestones ]
/
Role of natural killer cells in innate resistance to protozoan infections.
[ Milestones ]
/
Strategies for Facilitating Regulatory Pathways
[ Milestones ]
/
The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.
[ Milestones ]
/
The role of dendritic cells in the initiation of host resistance to Toxoplasma gondii.
[ Milestones ]
/
The role of IL-12 in regulation of T helper cell subsets in vivo. Lessons from experimental cutaneous leishmaniasis
[ Milestones ]
/
The role of the innate immune response in Th1 cell development following Leishmania major infection
[ Milestones ]
/
The vaccines consistency approach project: an EPAA initiative
[ Milestones ]
/
Toxoplasma gondii: evidence for interleukin-12-dependent and-independent pathways of interferon-gamma production induced by an attenuated parasite strain.
[ Milestones ]
/
Transcutaneous Immunization for Enteric Vaccines
[ Milestones ]
/
Transcutaneous immunization of domestic animals: opportunities and challenges.
[ Milestones ]
/
Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli.
[ Milestones ]
/
Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants
[ Milestones ]
/
Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants.
[ Milestones ]
/
Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge
[ Milestones ]
/
